+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Vulvodynia Treatment Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025

  • ID: 4807789
  • Report
  • June 2019
  • Region: Global
  • 119 pages
  • 360iResearch
UP TO OFF
until May 31st 2020
1 of 3

FEATURED COMPANIES

  • Allergan, Inc.
  • Depomed Inc.
  • Dipharma Francis S.r.l.
  • Eli Lilly and Company
  • Lumen Therapeutics, LLC
  • Novartis Pharmaceuticals
  • MORE
The Global Vulvodynia Treatment Market is expected to grow from USD 36,801.67 Million in 2018 to USD 66,902.56 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.91%.

The positioning of the Global Vulvodynia Treatment Market vendors in the FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

The report explores the recent significant developments by the leading vendors and innovation profiles in the Global Vulvodynia Treatment Market including are Depomed Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Pfizer Inc., Sanofi Aventis, Upsher-Smith Laboratories, LLC, Allergan, Inc., AstraZeneca Pharmaceuticals, Cellegy Pharmaceuticals, Inc., Dipharma Francis S.r.l., Lumen Therapeutics, LLC, Novartis Pharmaceuticals, and VuVatech LLC.

On the basis of Type, the Global Vulvodynia Treatment Market is examined across Biofeedback and Physical Therapy, Intralesional Injections, Oral Treatment, Surgical Treatment, and Topical Treatments.

On the basis of Indication, the Global Vulvodynia Treatment Market is examined across Generalized Vulvodynia and Localized Vulvodynia.

On the basis of Providers, the Global Vulvodynia Treatment Market is examined across Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies, and Research & Development Centres.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:

The market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Vulvodynia Treatment Market
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Vulvodynia Treatment Market
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Vulvodynia Treatment Market
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Vulvodynia Treatment Market
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Vulvodynia Treatment Market

The report answers questions such as:

1. What is the market size of the Vulvodynia Treatment market?
2. What are the factors that affect the growth in the Global Vulvodynia Treatment Market over the forecast period?
3. What is the competitive position in the Global Vulvodynia Treatment Market?
4. Which are the best product areas to be invested in over the forecast period in the Global Vulvodynia Treatment Market?
5. What are the opportunities in the Global Vulvodynia Treatment Market?
6. What are the modes of entering the Global Vulvodynia Treatment Market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan, Inc.
  • Depomed Inc.
  • Dipharma Francis S.r.l.
  • Eli Lilly and Company
  • Lumen Therapeutics, LLC
  • Novartis Pharmaceuticals
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. FPNV Positioning Matrix
2.3.2.1. Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support

3. Executive Summary
3.1. Outlook in the Vulvodynia Treatment Market
3.1.1. Need to detect chronic vulvar pain without an identifiable cause
3.1.2. Biofeedback therapy gaining traction during
3.2. Opportunities in the Vulvodynia Treatment Market

4. Premium Insight
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Increasing awareness about vulvodynia
4.2.2. Restraints
4.2.2.1. Unidentified causes and limited diagnosis options
4.2.3. Opportunities
4.2.3.1. Doctors offering self-care and treatments for vulvodynia
4.2.3.2. Prolonged availability of off-label drugs
4.2.4. Challenges
4.2.4.1. Limited familiarity of health care providers with vulvodynia
4.3. Porter's Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
4.4.1. Vulvodynia Epidemiological Data & Trend

5. Global Vulvodynia Treatment Market, by Type
5.1. Overview
5.2. Market Sizing & Forecasting
5.3. Biofeedback and Physical Therapy
5.4. Intralesional Injections
5.5. Oral Treatment
5.6. Surgical Treatment
5.7. Topical Treatments

6. Global Vulvodynia Treatment Market, by Indication
6.1. Overview
6.2. Market Sizing & Forecasting
6.3. Generalized Vulvodynia
6.4. Localized Vulvodynia

7. Global Vulvodynia Treatment Market, by Providers
7.1. Overview
7.2. Market Sizing & Forecasting
7.3. Hospitals & Care Providers
7.4. Pharmaceutical & Biotechnology Companies
7.5. Research & Development Centres

8. Global Vulvodynia Treatment Market, by Geography
8.1. Overview
8.2. Market Sizing & Forecasting
8.3. Americas
8.3.1. Overview
8.3.2. Market Sizing & Forecasting
8.3.3. Argentina
8.3.4. Brazil
8.3.5. Canada
8.3.6. Mexico
8.3.7. United States
8.4. Asia-Pacific
8.4.1. Overview
8.4.2. Market Sizing & Forecasting
8.4.3. Australia
8.4.4. China
8.4.5. India
8.4.6. Japan
8.5. Europe, Middle East & Africa
8.5.1. Overview
8.5.2. Market Sizing & Forecasting
8.5.3. France
8.5.4. Germany
8.5.5. Italy
8.5.6. Spain
8.5.7. United Kingdom

9. Competitive Landscape
9.1. FPNV Positioning Matrix for Global Vulvodynia Treatment Market
9.2. Market Vendor Ranking Analysis for Global Vulvodynia Treatment Market
9.3. Competitive News Feed Analysis for Global Vulvodynia Treatment Market

10. Company Usability Profiles
10.1. Depomed Inc.
10.1.1. Overview
10.1.2. Strategy
10.1.3. SWOT
10.2. Eli Lilly and Company
10.2.1. Overview
10.2.2. Strategy
10.2.3. SWOT
10.3. Janssen Pharmaceuticals, Inc.
10.3.1. Overview
10.3.2. Strategy
10.3.3. SWOT
10.4. Noven Pharmaceuticals, Inc.
10.4.1. Overview
10.4.2. Strategy
10.4.3. SWOT
10.5. Pfizer Inc.
10.5.1. Overview
10.5.2. Strategy
10.5.3. SWOT
10.6. Sanofi Aventis
10.6.1. Overview
10.6.2. Strategy
10.6.3. SWOT
10.7. Upsher-Smith Laboratories, LLC
10.7.1. Overview
10.7.2. Strategy
10.7.3. SWOT
10.8. Allergan, Inc.
10.9. AstraZeneca Pharmaceuticals
10.10. Cellegy Pharmaceuticals, Inc.
10.11. Dipharma Francis S.r.l.
10.12. Lumen Therapeutics, LLC
10.13. Novartis Pharmaceuticals
10.14. VuVatech LLC

11. Appendix
11.1. Discussion Guide
11.2. Top Reports
11.2.1. Global Crane Rental Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.2. Global Computer Vision Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.3. Global Payment Gateway Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.4. Global B2B Travel Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.5. Global Varicose Vein Treatment Devices Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.3. Author Details
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Depomed Inc.
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi Aventis
  • Upsher-Smith Laboratories, LLC
  • Allergan, Inc.
  • AstraZeneca Pharmaceuticals
  • Cellegy Pharmaceuticals, Inc.
  • Dipharma Francis S.r.l.
  • Lumen Therapeutics, LLC
  • Novartis Pharmaceuticals
  • VuVatech LLC
Note: Product cover images may vary from those shown
Adroll
adroll